<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9723">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05691634</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A02758-33</org_study_id>
    <nct_id>NCT05691634</nct_id>
  </id_info>
  <brief_title>Prospective Study Evaluating the Clinical Tolerance of Skin Tattoos During MRI Examinations (TATOU - IRM)</brief_title>
  <acronym>TATOU - IRM</acronym>
  <official_title>Prospective Study Evaluating the Clinical Tolerance of Skin Tattoos During MRI Examinations (TATOU - IRM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elsan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cimror</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Elsan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRI examinations are potential sources of complications related to the displacement of&#xD;
      ferromagnetic objects, but also to heating effects that can go as far as burns. This&#xD;
      overheating can be caused by contact with external equipment (sensors, cables, etc.).&#xD;
      Patients with skin tattoos may experience specific complications as tingling or &quot;burning&quot;&#xD;
      felt at the site of the tattoo. They can be followed by a transient erythema with edema&#xD;
      around the reversible tattoo in 12 and 72 hours. One observation of severe 2nd degree burns&#xD;
      has been reported. They would be linked to the presence of metallic salts in the dermis,&#xD;
      resulting from interactions between the pigments and the magnetic field but their mechanisms&#xD;
      are poorly identified and divergent.&#xD;
&#xD;
      The aim of this study is to assess the rate of MRI causing complications in patients with&#xD;
      tattoos.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2023</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of MRIs resulting in at least one complication in patients with tattoos.</measure>
    <time_frame>1 day</time_frame>
    <description>Complications are defined by the occurrence of symptoms felt by the patient (tingling, stinging, burning, redness, swelling) and by the occurrence of side effects visible to the operator (redness, oedema/tumefaction, others) and confirmed by the investigator present during the examination.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Tattoo Disorder</condition>
  <condition>MRI</condition>
  <arm_group>
    <arm_group_label>Patient with tatoo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Patient with a tatoo will perform an MRI. The possible symptoms during the MRI or after MRI will then be described (duration, type,...).</description>
    <arm_group_label>Patient with tatoo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Likert scale questionnaire</intervention_name>
    <description>The patient will appreciate his feeling after MRI on a Likert scale (from 1 to 5)</description>
    <arm_group_label>Patient with tatoo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient&#xD;
&#xD;
          -  tattoo patient&#xD;
&#xD;
          -  Ability to answer the questionnaire&#xD;
&#xD;
          -  Affiliated patient or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient having been informed and not objecting to the research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Patient unable to understand and respond to questionnaires due to language&#xD;
             difficulties or cognitive impairment&#xD;
&#xD;
          -  Patient objecting to research&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Protected patient: adult under guardianship, curatorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine Bagard</last_name>
    <phone>04 73 74 78 38</phone>
    <email>christine.gimbergues@laposte.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Duband Sandrine</last_name>
    <email>sduband@polesanterepublique.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pôle Santé République</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine BAGARD, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>March 9, 2023</last_update_submitted>
  <last_update_submitted_qc>March 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tattoo disorder</keyword>
  <keyword>MRI</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

